| Chronic Lymphocytic Leukemia |
1 |
1 |
| Biologic Therapy |
0 |
0.95 |
| Antineoplastic Drug |
0 |
0.94 |
| Monoclonal Antibody |
0 |
0.81 |
| Patient Safety |
0 |
0.49 |
| Adverse Effects |
0 |
0.45 |
| Otolaryngology |
0 |
0.38 |
| Lymphoma |
0 |
0.27 |
| Mantle Cell Lymphoma |
0 |
0.25 |
| Targeted Cancer Therapy |
0 |
0.22 |
| Genomic Medicine |
0 |
0.19 |
| Arrhythmia |
0 |
0.18 |
| Cancer |
0 |
0.18 |
| Tyrosine Kinase Inhibitor |
0 |
0.13 |
| Upper Respiratory Tract Infection |
0 |
0.13 |
| Arthralgia |
0 |
0.09 |
| Atrial Fibrillation |
0 |
0.09 |
| Blood |
0 |
0.09 |
| Chemotherapy |
0 |
0.09 |
| Diarrhea |
0 |
0.09 |
| Genetics |
0 |
0.09 |
| Hemorrhage |
0 |
0.09 |
| Hospital |
0 |
0.09 |
| Hypertension |
0 |
0.09 |
| Leukemia |
0 |
0.09 |
| Medical Oncology |
0 |
0.09 |
| New York |
0 |
0.09 |
| Respiratory Tract |
0 |
0.09 |
| Tyrosine Kinase |
0 |
0.09 |